Neurologic Complications of Cancer Therapies

Nowadays, cancer treatment has been a big challenge to healthcare systems. Most of clinical anti-cancer therapies are toxic and cause adverse effects to human body. Therefore, current trend in science is seeking and screening of natural compounds which possess antineoplastic activities to utilize in treatment. Uvaria L. - Annonaceae includes approximately 175 species spreading over tropical areas of Asia, Australia, Africa and America. Studies on chemical compositions and pharmacological effects of Uvaria showed that several compound classes in this genus such as alkaloid, flavonoid, cyclohexen derivaties, acetogenin, steroid, terpenoid, etc. indicate considerable biological activities, for example anti-tumor, anti-cancer, antibacterial, antifungal, antioxidant, etc. Specifically, anti-cancer activity of fractions of extract and pure isolated compounds stands out for cytotoxicity against many cancer cell lines. This study provides an overview of anti-cancer activity of Uvaria and suggests a potential for further studies on seeking and developing novel anti-cancer compounds. Key words: Anti-cancer, Uvaria.

Download Full-text

Faculty Opinions recommendation of Neurologic complications after chlorhexidine antisepsis for spinal anesthesia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14267129.15779381 ◽

2012 ◽

Author(s):

Vincent Chan ◽

Ki Jinn Chin

Keyword(s):

Spinal Anesthesia ◽

Neurologic Complications

Download Full-text

Faculty Opinions recommendation of Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737615009.793573317 ◽

2020 ◽

Author(s):

Maida Taylor

Keyword(s):

Breast Cancer ◽

Cancer Therapies

Download Full-text

A Rational Sequencing of Anti-Angiogenic Agents as Second-Line Treatment Choice for mCRC Patients Progressing After a Bevacizumab-Based First Line

healthbook TIMES Oncology Hematology ◽

10.36000/hbt.oh.2020.03.010 ◽

2020 ◽

pp. 14-19

Author(s):

Sara De Dosso

Keyword(s):

Acquired Resistance ◽

Predictive Biomarker ◽

Cancer Therapies ◽

Vascular Endothelial ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Vegf Pathway ◽

Effective Choice ◽

Endothelial Growth Factor

A large proportion of patients with metastatic colorectal cancer (mCRC) experience disease progression after first-line treatment with chemotherapy and bevacizumab, an anti-angiogenic agent, as a result of acquired resistance. However, blocking angiogenesis by targeted therapy towards the vascular endothelial growth factor (VEGF) pathway still forms an essential part of the second-line treatment strategy. Although three approved evidence-based choices for angiogenic agents (continuing treatment with bevacizumab, ramucirumab and aflibercept) are currently available in the second line, making the most effective choice is challenging due to the lack of studies directly comparing these agents. Moreover, despite huge investigational efforts, no predictive biomarker for anti-angiogenic cancer therapies could be identified so far.

Download Full-text

Targeting the Hippo Pathway for Anti-cancer Therapies

Current Medicinal Chemistry ◽

10.2174/0929867322666151002112256 ◽

2015 ◽

Vol 22 (35) ◽

pp. 4104-4117 ◽

Cited By ~ 12

Author(s):

Rui Gong ◽

Fa-Xing Yu

Keyword(s):

Hippo Pathway ◽

Cancer Therapies ◽

Anti Cancer ◽

The Hippo Pathway

Download Full-text